PPARG and type 2 diabetes mellitus: PPARG and RXR have been suggested as therapeutic targets for T2D, due to PPARG role in regulating genes associated to glucose homeostasis [69], and RXR for regulating glucose-stimulated insulin secretion and affecting a number of genes that have been implicated in β-cell function and differentiation [70].